Prescription medicine
Tapinarof Brand names: Vtama
Tapinarof (Vtama) is a prescription medicine with an FDA approval on record since 2022. No generic is listed; pharmacies paid $25.23 per gram (Vtama 1% cream) in the October 7, 2026 NADAC survey.
- No generic listed
Check it at the source: the tapinarof FDA label on DailyMed (effective May 28, 2025); the NDA 215272 record on Drugs@FDA; every tapinarof label on DailyMed.
Highlights of the record
FDA label of May 28, 2025; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageVTAMA cream, 1% is an aryl hydrocarbon receptor agonist indicated for: the topical treatment of plaque psoriasis in adults.
Forms and strengths
- 10 mg/g
Cream.
On the market
- Earliest approval on file
- May 23, 2022 Vtama, Organon Llc; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 1 of which 0 under generic applications, 1 under brand applications, repackagers included
- Last listed patent
- December 18, 2039 Vtama cream; not a generic launch date
Supply and safety
- Pharmacy cost (NADAC)
- $25.23 per gram Vtama 1% cream
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 1,751 through July 30, 2026
What is tapinarof used for?
From the label: indications and usageVTAMA cream, 1% is an aryl hydrocarbon receptor agonist indicated for: the topical treatment of plaque psoriasis in adults. ( 1.1 ) the topical treatment of atopic dermatitis in adults and pediatric patients 2 years of age and older. ( 1.2 ) 1.1 Plaque Psoriasis VTAMA ® cream is indicated for the topical treatment of plaque psoriasis in adults. 1.2 Atopic Dermatitis VTAMA cream is indicated for the topical treatment of atopic dermatitis in adults and pediatric patients 2 years of age and older.
Conditions named in the indications of tapinarof's FDA labels, with every medicine labeled for each:
FDA pharmacologic class: Aryl Hydrocarbon Receptor Agonist.
Source: FDA drug label (VTAMA), Organon LLC, effective May 28, 2025 (SPL set 9309d20f-8cd4-4c96-93fa-7f730e83c7ab), via openFDA; the full label on DailyMed
Is there a generic for tapinarof (Vtama)?
No generic tapinarof is approved (Drugs@FDA, October 8, 2026).
The Orange Book lists 12 patents for Vtama cream: the compound patent runs to November 13, 2038, and the last listed entry to December 18, 2039. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.
- 2022 earliest approval on file
- 2039 last listed patent
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for tapinarof (Vtama)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $25.23 per gram (Vtama 1% cream), up 5% from $24.12 on October 8, 2025. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Vtama 1% cream (brand)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Vtama 1% cream | Brand | $25.23 per gram | n/a | +5% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
What do FAERS reports show for tapinarof?
The FDA Adverse Event Reporting System holds 1,751 reports that list tapinarof among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 6 are coded as a death and 60 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as tapinarof?
10 other medicines are given the same way (topical) and in the same FDA class as tapinarof or labeled mainly for the same use (psoriasis), the same class first. Psoriasis lists all 38 medicines labeled for it, by any route. The first 8 are below. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (topical) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Clobetasol | Psoriasis | 40 labelers | $0.126 per gram 0.05% ointment | No current entry |
| Fluocinolone | Psoriasis, Eczema (atopic dermatitis) | 15 labelers | $0.171 per mL 0.01% scalp oil | No current entry |
| Desoximetasone | Psoriasis | 13 labelers | $0.369 per gram 0.25% ointment | No current entry |
| Coal tar | Psoriasis | none listed | $0.0088 per mL 0.5% shampoo | No current entry |
| Halobetasol | Psoriasis | 6 labelers | $0.620 per gram 0.05% ointmnt | No current entry |
| Tazarotene | Psoriasis | 6 labelers | $6.11 per gram 0.1% gel | No current entry |
| Betamethasone and calcipotriene | Psoriasis | 5 labelers | $1.81 per gram 0.005%-0.064% ointment | No current entry |
| Calcipotriene | Psoriasis | 6 labelers | $1.05 per gram 0.005% cream | No current entry |
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
What next?
- Alternatives to tapinarof
- 10 medicines for the same use
- Tapinarof side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other